H.U. Group Holdings, Inc.
4544・Prime Market・Services
Laboratory Testing & Related Services (LTS)
A core mainstay segment accounting for approximately 64% of group revenue, centered on the largest domestic contract clinical laboratory testing business
| Period | Current | Previous | Change |
|---|---|---|---|
| External customer revenue | ¥157,297 million | ¥153,014 million | ↑ |
| Operating profit (loss) | ¥31 million | △¥4,638 million | ↑ |
| Segment assets | ¥102,292 million | ¥108,603 million | ↓ |
| Depreciation and amortization | ¥13,598 million | ¥12,245 million | ↑ |
| Increase in property, plant and equipment and intangible assets | ¥3,870 million | ¥6,316 million | ↓ |
| Amortization of goodwill | ¥42 million | ¥43 million | — |
Business Details
Centered on SRL Inc., the segment provides contract specialty and routine testing services to a broad range of medical institutions, from large hospitals to small and medium-sized clinics. It also handles health checkup outsourcing and food, environmental, and cosmetics testing. The segment is pursuing productivity gains and profitability improvement through the full-scale operation of the H.U. Bioness Complex. In FY2026 (ending March 2026), price optimization and improvements in testing operations proved effective, achieving a turnaround from an operating loss to operating profit.
Recent Overview
Achieved a turnaround to operating profit through price optimization and improved testing operations
External customer revenue for FY2026 (ending March 2026) was ¥157,297 million (up 2.8% year on year). Revenue increased due to growth in genetic-related testing, led by cancer genomic testing, and specialty testing. On the profit side, in addition to the revenue increase in the base business, an increase in marginal profit driven by price optimization and improvements in testing operations centered on the fully operational H.U. Bioness Complex enabled a turnaround from the prior period's operating loss of ¥4,638 million to operating profit of ¥31 million.
Key Products
Growth Drivers
- Growth in the base business of cancer genomic testing, genetic-related testing, and specialty testing (revenue up 2.8% year on year)
- Improved testing operations and higher fixed-cost absorption rates through full-scale operation of the H.U. Bioness Complex
- Increase in marginal profit through price optimization
- Group integration strategy (cross-selling via HUF and cost reduction through introduction of proprietary reagents)
- Business expansion into the preventive healthcare and wellness field (PHR service "With Wellness®" and mail-in testing)
Risks
- Ongoing pressure to suppress laboratory testing fees due to healthcare cost reduction policies
- Risk of decreased outsourced testing volume due to deteriorating financial conditions at medical institutions
- Risk that the utilization rate and productivity of the H.U. Bioness Complex fall short of plan (given its large fixed-cost burden)
- Continued risk of equity-method investment losses amid a reduced investment balance of ¥462 million in equity-method affiliates
- Risk of delayed profitability improvement due to rising labor and energy costs
Last updated: June 15, 2026